PP
FPRX

Paloma Partners’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Paloma Partners’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-14,704
Closed -$67K – 2335
2019
Q4 		$67K Buy
+14,704
New +$58.2K ﹤0.01% 2070
2019
Q3 		– Sell
-37,300
Closed -$225K – 2414
2019
Q2 		$225K Buy
+37,300
New +$357K ﹤0.01% 1478

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Paloma Partners's FPRX Position: Q1 2020 in Review

Paloma Partners sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2020, closing a stake of 14,704 shares — an estimated $67K sold.

Paloma Partners first reported a position in FPRX in Q2 2019 and held it in 2 quarters. The position peaked at $225K in Q2 2019. 87 funds tracked by Wall St. Rank hold FPRX as of Q1 2020.

  • Paloma Partners reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • Paloma Partners sold 14,704 Five Prime Therapeutics, Inc. shares in Q1 2020, an estimated $67K.
  • Paloma Partners first reported a position in Five Prime Therapeutics, Inc. in Q2 2019 and held it in 2 quarters.
  • Paloma Partners's Five Prime Therapeutics, Inc. position peaked at $225K in Q2 2019.
  • 87 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.